CFTR Related Pancreatitis Study
Primary Purpose
Cystic Fibrosis, CFTR Gene Dysfunction
Status
Withdrawn
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Beta Adrenergic Sweat Test
Sponsored by
About this trial
This is an interventional diagnostic trial for Cystic Fibrosis
Eligibility Criteria
Inclusion Criteria:
- Age : 4 years and older
- Diagnosis: Acute recurrent pancreatitis or chronic pancreatitis
History: at least one of the following:
- Carry one or two CFTR mutations
- Borderline sweat chloride levels
- Has Family History of CF
Has had positive CF Newborn screening
Exclusion Criteria:
- Pregnant females: will be excluded at screening.
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Interventional Arm
Arm Description
All patients consented to study will undergo study intervention which is Beta-adrenergic sweat test (Beta sweat test) using evaporimeter. It takes about 60 minutes to complete this test. Once this test is completed, patient will be considered to have completed the study.
Outcomes
Primary Outcome Measures
Assessment of CFTR function using the Beta Adrenergic Sweat Secretion Test
CFTR function assessment of patients with acute recurrent or chronic pancreatitis by using Beta adrenergic sweat test.
Secondary Outcome Measures
Full Information
NCT ID
NCT04274413
First Posted
February 16, 2020
Last Updated
July 12, 2021
Sponsor
The Hospital for Sick Children
Collaborators
The National Pancreas Foundation
1. Study Identification
Unique Protocol Identification Number
NCT04274413
Brief Title
CFTR Related Pancreatitis Study
Official Title
Assessing CFTR Function in Patients With CFTR Related Pancreatitis Using a Novel Sweat Test
Study Type
Interventional
2. Study Status
Record Verification Date
July 2021
Overall Recruitment Status
Withdrawn
Why Stopped
Due to funding and Covid-19 pandemic
Study Start Date
February 1, 2021 (Actual)
Primary Completion Date
February 1, 2021 (Actual)
Study Completion Date
February 1, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The Hospital for Sick Children
Collaborators
The National Pancreas Foundation
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The main causes of acute recurrent pancreatitis (ARP) or chronic pancreatitis (CP) in children are defects in genes that have been associated to pancreatitis. Among these gene defects CFTR gene mutations are commonly found, 34% ARP and 23% CP . Since not every CFTR gene mutations clinically manifest, just identifying these CFTR gene mutations may not help to establish a clear role of this defect in the etiology of the individual ARP/CP. The novel beta-adrenergic sweat secretion test is a very sensitive test to detect small abnormalities in CFTR function in form of a linear gene-function relation. By identifying even mild CFTR defects, in future will help in finding the role of CFTR modulators and providing treatment to these patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cystic Fibrosis, CFTR Gene Dysfunction
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Evaporimeter TEWL probes, model RG-1
Masking
None (Open Label)
Allocation
N/A
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Interventional Arm
Arm Type
Experimental
Arm Description
All patients consented to study will undergo study intervention which is Beta-adrenergic sweat test (Beta sweat test) using evaporimeter. It takes about 60 minutes to complete this test. Once this test is completed, patient will be considered to have completed the study.
Intervention Type
Combination Product
Intervention Name(s)
Beta Adrenergic Sweat Test
Intervention Description
In Beta Sweat Test - sweat secretion will be stimulated by injecting a series of drugs within the skin surface. Small needles will be used to inject minute amounts of each drug. Before and after each skin injection, the skin will be cleaned using an alcohol swab.
Two sensor probes will be strapped to the forearm with rubber bands in position just above the injection site.
Under the first probe, injection atropine will be given in one small area of the skin.
Under the second probe, first injection carbachol will be given in one small area of the skin.
Next, at the second probe area, the normal sweating will be stopped for awhile by injecting a drug called atropine.
Lastly, beta-adrenergic sweating will be stimulated by injecting a combination of the following drugs: atropine, isoproterenol, and aminophylline (β-cocktail). Using probes, all sweat rate readings will be recorded.
Primary Outcome Measure Information:
Title
Assessment of CFTR function using the Beta Adrenergic Sweat Secretion Test
Description
CFTR function assessment of patients with acute recurrent or chronic pancreatitis by using Beta adrenergic sweat test.
Time Frame
60 mins
10. Eligibility
Sex
All
Minimum Age & Unit of Time
4 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age : 4 years and older
Diagnosis: Acute recurrent pancreatitis or chronic pancreatitis
History: at least one of the following:
Carry one or two CFTR mutations
Borderline sweat chloride levels
Has Family History of CF
Has had positive CF Newborn screening
Exclusion Criteria:
Pregnant females: will be excluded at screening.
12. IPD Sharing Statement
Learn more about this trial
CFTR Related Pancreatitis Study
We'll reach out to this number within 24 hrs